Vicore Pharma Holding AB (publ) (STO:VICO)

Sweden flag Sweden · Delayed Price · Currency is SEK
6.53
+0.03 (0.46%)
Apr 15, 2025, 2:56 PM CET
-61.86%
Market Cap 1.52B
Revenue (ttm) 109.35M
Net Income (ttm) -168.63M
Shares Out 234.58M
EPS (ttm) -1.23
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 123,593
Average Volume 304,420
Open 6.48
Previous Close 6.50
Day's Range 6.42 - 6.65
52-Week Range 6.09 - 24.10
Beta 0.54
RSI 38.76
Earnings Date May 6, 2025

About Vicore Pharma Holding AB

Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases. It develops C21, an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary arterial hypertension. The company is also developing Almee, an investigational medical device in clinical development that has completed Phase III clinical stage... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Employees 29
Stock Exchange Nasdaq Stockholm
Ticker Symbol VICO
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.